Education
About Us
Working with TipRanks
Follow Us
Edgewise Therapeutics (EWTX)
NASDAQ:EWTX
Total Valuation
Edgewise Therapeutics has a market cap or net worth of $2.41B. The enterprise value is $1.15B.
Market Cap$2.41B
Enterprise Value$1.15B
Share Statistics
Edgewise Therapeutics has 105,868,430 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding105,868,430
Owned by Insiders1.39%
Owned by Institutions75.37%
Financial Efficiency
Edgewise Therapeutics’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -34.16%.
Return on Equity (ROE)-0.29
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-34.16%
Return on Capital Employed (ROCE)-0.34
Revenue Per Employee0.00
Profits Per Employee-1.14M
Employee Count117
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Edgewise Therapeutics is ―. Edgewise Therapeutics’s PEG ratio is 2.41.
PE Ratio―
PS Ratio0.00
PB Ratio5.37
Price to Fair Value5.37
Price to FCF-22.36
Price to Operating Cash Flow-17.65
PEG Ratio2.41
Income Statement
In the last 12 months, Edgewise Therapeutics had revenue of 0.00 and earned -133.81M in profits. Earnings per share was -1.45.
Revenue0.00
Gross Profit0.00
Operating Income-158.83M
Pretax Income-133.81M
Net Income-133.81M
EBITDA-156.54M
Earnings Per Share (EPS)-1.45
Cash Flow
In the last 12 months, operating cash flow was -132.18M and capital expenditures -457.00K, giving a free cash flow of -132.64M billion.
Operating Cash Flow-132.18M
Free Cash Flow-132.64M
Free Cash Flow per Share-1.25
Dividends & Yields
Edgewise Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.38
52-Week Price Change-29.67%
50-Day Moving Average16.41
200-Day Moving Average17.02
Relative Strength Index (RSI)70.14
Average Volume (3m)1.02M
Important Dates
Edgewise Therapeutics upcoming earnings date is Feb 19, 2026, After Close (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateFeb 19, 2026
Ex-Dividend Date―
Financial Position
Edgewise Therapeutics as a current ratio of 19.93, with Debt / Equity ratio of 0.74%
Current Ratio19.93
Quick Ratio19.93
Debt to Market Cap<0.01
Net Debt to EBITDA0.28
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Edgewise Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Edgewise Therapeutics EV to EBITDA ratio is -18.48, with an EV/FCF ratio of -22.03.
EV to Sales0.00
EV to EBITDA-18.48
EV to Free Cash Flow-22.03
EV to Operating Cash Flow-22.29
Balance Sheet
Edgewise Therapeutics has $563.34M in cash and marketable securities with $4.18M in debt, giving a net cash position of $559.16M billion.
Cash & Marketable Securities$563.34M
Total Debt$4.18M
Net Cash$559.16M
Net Cash Per Share$5.28
Tangible Book Value Per Share$4.97
Margins
Gross margin is -111.05%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-111.05%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Edgewise Therapeutics is $37.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$37.00
Price Target Upside66.22% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast-5.73%